Elliot started his career as clinical pharmacist performing therapeutic drug monitoring and providing pharmaceutical care in hospital and community settings. After obtaining his MSc from Western University in London, Canada, Elliot oversaw biopharmaceutics and scientific affairs for Genpharm, a subsidiary of Merck KGaA (later acquired by Mylan) which included responsibility for clinical operations, pharmacokinetic analysis and regulatory support for generic and innovative submissions to the FDA, Health Canada and other jurisdictions.
Prior to joining Certara, Elliot was responsible for clinical pharmacology and pharmacometrics at Celerion. In his capacity at Celerion, Elliot oversaw study design, data analysis and interpretation for clinical pharmacology studies including first-in-human, drug-drug interactions, mass balance and special population trials. Elliot has worked as a clinical pharmacology consultant for Santarus, Auspex and several other small pharma and biotech companies supporting FDA and EMA interactions and NDA submissions.
Elliot has also completed a PhD at the University of Waterloo (Waterloo, Canada) in model-based drug development with a particular focus in physiologically and population based pharmacokinetic modelling of subcutaneously administered large molecules.
In his free time, Elliot enjoys spending time at the hockey rink with his children, playing and watching basketball, and anything to do with Star Wars.